Evidence map›Paper›PMID 33736701›Full record

ArticleStem cell research & therapy2021

Alterations of mesenchymal stromal cells in cerebrospinal fluid: insights from transcriptomics and an ALS clinical trial.

Ashley A Krull, Deborah O Setter, Tania F Gendron, Sybil C L Hrstka, Michael J Polzin, Joseph Hart, Amel Dudakovic, Nicolas N Madigan, Allan B Dietz, Anthony J Windebank and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Open-Spaced Ridged Hydrogel Scaffolds Containing TiOInternational journal of molecular sciences · 2023
    Article
  6. Review
  7. Genetic profiling of human bone marrow mesenchymal stromal cells afterFrontiers in bioengineering and biotechnology · 2022
    Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ashley A KrullDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Deborah O SetterDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Tania F GendronDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Sybil C L HrstkaDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Michael J PolzinDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Joseph HartDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Amel DudakovicDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Nicolas N MadiganDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Allan B DietzDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Anthony J WindebankDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Andre J van WijnenDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Nathan P StaffDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. Staff.Nathan@mayo.edu.ORCID 0000-0001-6760-3859
Mayo Clinic · USMayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stromal cells (MSCs) have been studied with increasing intensity as clinicians and researchers strive to understand the ability of MSCs to modulate disease progression and promote tissue regeneration. As MSCs are used for diverse applications, it is important to appreciate how specific physiological environments may stimulate changes that alter the phenotype of the cells. One need for neuroregenerative applications is to characterize the spectrum of MSC responses to the cerebrospinal fluid (CSF) environment after their injection into the intrathecal space. Mechanistic understanding of cellular biology in response to the CSF environment may predict the ability of MSCs to promote injury repair or provide neuroprotection in neurodegenerative diseases.

methodsIn this study, we characterized changes in morphology, metabolism, and gene expression occurring in human adipose-derived MSCs cultured in human (hCSF) or artificial CSF (aCSF) as well as examined relevant protein levels in the CSF of subjects treated with MSCs for amyotrophic lateral sclerosis (ALS).

resultsOur results demonstrated that, under intrathecal-like conditions, MSCs retained their morphology, though they became quiescent. Large-scale transcriptomic analysis of MSCs revealed a distinct gene expression profile for cells cultured in aCSF. The aCSF culture environment induced expression of genes related to angiogenesis and immunomodulation. In addition, MSCs in aCSF expressed genes encoding nutritional growth factors to expression levels at or above those of control cells. Furthermore, we observed a dose-dependent increase in growth factors and immunomodulatory cytokines in CSF from subjects with ALS treated intrathecally with autologous MSCs.

conclusionsOverall, our results suggest that MSCs injected into the intrathecal space in ongoing clinical trials remain viable and may provide a therapeutic benefit to patients.

Indexed as

Amyotrophic Lateral SclerosisMesenchymal Stem CellsMesenchymal Stem Cell TransplantationCytokinesHumansImmunomodulationTranscriptomeCytokinesAmyotrophic lateral sclerosisCerebrospinal fluidGene expressionGrowth factorsHuman studiesMesenchymal stromal cellNeuroinflammation

Identifiers

PMID33736701
PMCPMC7977179
OpenAlexW3137195984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.